EIF4BP9: A Potential Drug Target and Biomarker (G100129692)

Target Name: EIF4BP9

NCBI ID: G100129692

EIF4BP9

Other Name(s): eukaryotic translation initiation factor 4B pseudogene 9 | Eukaryotic translation initiation factor 4B pseudogene 9

EIF4BP9: A Potential Drug Target and Biomarker

EIF4BP9, also known as EIF4BP9-ALZ, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the EIF4BP9 family, which is characterized by the presence of a unique N-terminal domain called N-WASP-1. The N-WASP-1 domain is known for its ability to interact with various protein partners, including casein kinase (CK) 3, which is a protein that is involved in many cellular processes, including cell signaling, protein-protein interactions, and DNA replication.

The Identification of EIF4BP9 as a Potential Drug Target

The potential drug target for EIF4BP9 was identified based on its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. EIF4BP9 has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. It is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other to carry out various functions.

In addition to its role in cell signaling, EIF4BP9 has also been shown to play a role in the regulation of DNA replication, which is the process by which a cell makes copies of its DNA. This is important for maintaining the genetic integrity of the cell, and is also involved in the development and progression of cancer.

The Potential Benefits of Treating EIF4BP9-Positive Diseases

The potential benefits of treating EIF4BP9-positive diseases are significant. For example, in cancer, EIF4BP9 has been shown to be involved in the regulation of cell adhesion, which is thought to contribute to the development and progression of cancer. By targeting EIF4BP9 with drugs that can inhibit its activity, it may be possible to treat cancer cells that have this protein.

In addition to its potential use in cancer, EIF4BP9 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease. This suggests that targeting EIF4BP9 with drugs that can inhibit its activity may be a promising approach to treating neurodegenerative diseases.

The Potential Risks of Treating EIF4BP9-Positive Diseases

While the potential benefits of treating EIF4BP9-positive diseases are significant, there are also potential risks to consider. For example, treating cancer cells that have EIF4BP9 may be associated with unintended side effects, such as the development of resistance to the drug. In addition, treating neurodegenerative diseases that are caused by EIF4BP9 may be associated with the worsening of symptoms, such as cognitive decline.

Conclusion

In conclusion, EIF4BP9 is a protein that is expressed in various tissues of the body and is involved in several cellular processes that are associated with various diseases. The potential drug target for EIF4BP9 was identified based on its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. While the potential benefits of treating EIF4BP9-positive diseases are significant, there are also potential risks to consider. Further research is needed to determine the most effective and safe treatments for EIF4BP9-positive diseases.

Protein Name: Eukaryotic Translation Initiation Factor 4B Pseudogene 9

The "EIF4BP9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4BP9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets